A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Bromocriptine (CYCLOSET)

Ergot Derivative class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval1998-01-13
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$12.5M in CY2024 Part D spend57K claims · 13K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.65/unit
8 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.02
Across all dosage forms in distribution.
Highest NADAC
$5.26
Range is tight.
Plans with PA
1 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Bromocriptine used for?

Bromocriptine is a Ergot Derivative medication tracked in Medicare Part D.

Is there a generic for Bromocriptine?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Bromocriptine?

Across 329 Part D plans, Bromocriptine averages $3.02/unit (NADAC). Lowest available: $1.65/unit. Highest in distribution: $5.26/unit.

Is Bromocriptine on the FDA shortage list?

No. Bromocriptine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Ergot Derivative2 alternatives in D1
01
Cabergoline
Ergot Derivative
$1.41Lowest NADAC
5Generic mfrs
$10.1MCY24 Part D spend
Compare →
02
Methylergonovine
Brand: Methergine
$5.66Lowest NADAC
8Generic mfrs
$503,249CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (8 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.